Immunology
Latest news and updates related to immunology
About Immunology coverage
The Immunology news hub on Global Investing News tracks 5 recent headlines that matter to investors, policy watchers, and market strategists. Use this page to monitor how Immunology developments affect earnings expectations, sector rotation, supply chains, regulation, and cross-asset volatility. Stories are grouped by source type — market data, company announcements, regulatory filings, and expert analysis — so you can scan the signal quickly without wading through duplicate wire copy. When a headline links to a full article, you will find expanded context, key facts, and prediction-market angles where available. Bookmark this hub if you follow Immunology across quarters; new items are added as our crawl pipeline ingests fresh sources throughout the trading day.
Explore related topics
Latest Immunology headlines
Market Data
(5)AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.
AbbVie's recent quarterly performance delivered a top and bottom-line beat, yet the subsequent share price decline highlights the market's intense focus on the post-Humira erosion cycle. While Humira sales fell roughly 36%—slightly better than the worst-case fears—investors are pivots from 'earnings beats' to the sustainability of long-term growth drivers Skyrizi and Rinvoq. These immunology successors showed impressive double-digit growth, but the market remains cautious about the rising competitive landscape and potential pricing pressures from the Inflation Reduction Act (IRA). Furthermore, AbbVie's aggressive M&A strategy, including the recent acquisitions of ImmunoGen and Cerevel Therapeutics, has increased the company's leverage and R&D spending, leading to a 'sell the news' reaction as traders digest updated full-year guidance that, while raised, may not have been ambitious enough to justify current valuations. Investors should closely monitor the uptake of Skyrizi in the ulcerative colitis market and any regulatory updates regarding the company's aesthetics portfolio (Botox), which continues to face headwinds from dampened consumer discretionary spending.
FDA Rejects Self-Injected Version of AstraZeneca’s Lupus Drug
The FDA's decision to issue a Complete Response Letter (CRL) for AstraZeneca’s self-administered pen version of Saphnelo (anifrolumab) represents a temporary setback for the company’s expansion into the lucrative immunology space. Saphnelo, already approved for intravenous (IV) administration for systemic lupus erythematosus (SLE) since 2021, was seeking this label expansion to improve patient convenience and gain market share from GSK’s Benlysta, which currently offers both IV and autoinjector options. The rejection is particularly significant as AstraZeneca aims to shift treatment from clinical settings to at-home care, a key trend in chronic disease management that drives higher adherence and long-term prescription volumes. While AstraZeneca noted that the FDA's concerns do not relate to the drug's safety or efficacy profile, the delay gives competitors a wider window to solidify their dominance in the subcutaneous market. Investors should monitor the upcoming feedback from the FDA regarding the specific device or manufacturing requirements needed for a resubmission. This event highlights the high regulatory bar for drug-device combinations, even for previously approved biologic compounds.
Why AbbVie Stock Trounced the Market in 2025
AbbVie's outperformance in 2025 marks a critical stabilization point for the pharmaceutical giant as it successfully navigates the post-exclusivity era of its blockbuster drug, Humira. While investors initially feared a 'patent cliff' revenue vacuum, AbbVie's strategic pivot toward its next-generation immunology assets, Skyrizi and Rinvoq, has yielded growth that exceeded consensus estimates. These two drugs have not only captured significant market share in plaque psoriasis and rheumatoid arthritis but have also expanded into new indications, effectively offsetting Humira's biosimilar erosion. Furthermore, the company's aggressive M&A strategy—highlighted by the integration of ImmunoGen and Cerevel Therapeutics—has bolstered its oncology and neuroscience pipelines, providing long-term cash flow visibility beyond immunology. In a year characterized by market volatility and shifting interest rate expectations, AbbVie's high-single-digit dividend growth and defensive profile made it a preferred vehicle for institutional capital seeking 'growth at a reasonable price' (GARP). Investors should now monitor upcoming Phase 3 data in its solid tumor pipeline and the potential impact of Medicare price negotiations under the Inflation Reduction Act, which remains the primary regulatory headwind for the sector.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie Inc. (ABBV) continues to navigate a pivotal transition period as it manages the post-exclusivity erosion of its flagship drug, Humira. Despite the entry of multiple biosimilars in the U.S. market, AbbVie has successfully mitigated revenue losses through the aggressive scaling of its next-generation immunology assets, Skyrizi and Rinvoq. These two drugs are projected to surpass Humira’s peak annual sales combined, providing a stable floor for long-term growth. Furthermore, the company’s recent $10.1 billion acquisition of ImmunoGen and the $8.7 billion buyout of Cerevel Therapeutics signal a strategic pivot toward oncology and neuroscience to diversify its portfolio beyond immunology. For investors, the significance lies in AbbVie’s ability to maintain its 'Dividend King' status while repositioning its pipeline for a post-Humira era. Looking forward, market participants should monitor the integration of these high-premium acquisitions and the upcoming regulatory decisions for its aesthetics and neuroscience pipelines. While patent cliffs remain a systemic risk in the pharmaceutical sector, AbbVie’s robust cash flow and successful 'bridge' strategy to newer therapies suggest a resilient outlook for value-oriented investors.
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026?
ADMA Biologics (ADMA) has demonstrated robust momentum with a 13.8% gain over the last quarter, significantly outperforming the broader biotech sector. This rally is underpinned by the company's successful pivot to profitability, driven by its specialized plasma-derived therapeutics used to treat primary immunodeficiency and prevent respiratory syncytial virus (RSV). For sophisticated investors, the focus shifts to the 2026 outlook, where management has provided highly optimistic guidance, fueled by vertical integration and the expansion of its plasma collection network. The company’s competitive advantage lies in its high-margin product mix, specifically BIVIGAM and ASCENIV, which are seeing increased clinical adoption. While the biotech sector has faced headwinds from high interest rates, ADMA’s status as a profitable, high-growth entity separates it from speculative pre-revenue peers. The primary forward-looking catalyst is the potential for further margin expansion as the company achieves economies of scale in its manufacturing process and continues to exceed quarterly revenue targets. Investors should monitor FDA regulatory filings and potential M&A activity in the plasma space, as ADMA remains a prime candidate for consolidation.
Get alerts for this topic
Subscribe to receive updates about "Immunology"